TheranosticTrials.org

Clinical Trial · NCT07664410

Theranostic PET for Target Validation and Tumor Detection

Overview

Patients are referred for theranostic PET using different tracers as part of clinical routine for tumor staging, re-staging, and therapy planning to our department. The aim of this study is to collect data on the expression of target molecules/receptors, proportion of PET positive tumor regions, positive predictive value, detection rate, reproducibility, and impact on clinical management of theranostic PET/CT or PET/MRI using novel theranostic PET tracers or other established PET tracers that are performed in theranostic concepts on patients receiving this imaging modality as part of clinical standard both at initial diagnosis and restaging before treatment decisions. Primary Endpoint: Association between PET uptake intensity in theranostic PET and histopathologic expression of the respective molecular target.

Sponsor

University Hospital, Essen

Contacts

Josephine Enste (CONTACT)

josephine.enste@uk-essen.de

+492017232073

David Kersting, MD PhD (PRINCIPAL_INVESTIGATOR)

Alina Toni Küper, MD (CONTACT)

alina.kueper@uk-essen.de

+492017232073

ClinicalTrials.gov

NCT07664410

Drug / Compound

Pentixafor

Isotope(s):
Target(s):
  • CXCR4
Ligand Class: Peptides
Chelator: DOTA

PSMA-1007

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

DOTATOC

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

FAPI-46

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA
Linker: piperazine

Eligibility

Inclusion

  • PET imaging with a theranostic PET tracer scheduled for staging or restaging of tumor types as part of clinical routine

Exclusion

  • Condition of patient which is critical to participate in this study in the discretion of the investigators